Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Post-Surgical Pain |
| Therapuetic Areas: | Musculoskeletal, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/4/2019 |
| Start Date: | March 29, 2019 |
| End Date: | December 31, 2019 |
| Contact: | Jessica Reynolds, BSN |
| Email: | jreynolds11@kumc.edu |
| Phone: | 913-588-0068 |
Prospective Study of Liposomal Bupivacaine for Pain Control of Split Thickness Skin Graft Donor Sites
Donor site pain study comparing post-operative donor site pain and opioid consumption after
use of Lidocaine or Liposomal Bupivicaine for split thickness skin graft harvesting in
patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness
burn wounds.
use of Lidocaine or Liposomal Bupivicaine for split thickness skin graft harvesting in
patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness
burn wounds.
This study is a prospective, randomized controlled trial. Study subjects are blinded to their
randomization to avoid bias. The control group will undergo split thickness autografting
using the standard protocol, involving injection of lidocaine with epinephrine at the donor
site. The experimental group will undergo injection of liposomal bupivacaine (Exparel) at the
time of harvest of the skin graft. Baseline pain levels will be obtained for all subjects
using a validated pain assessment scale. Postoperatively, time to first opioid pain
medication (excluding immediate postoperative recovery from anesthesia), total opioid
consumption on a daily basis, and donor site interval pain scores using a validated pain
assessment scale will be obtained. The experimental group will then be compared to the
control group to determine if there is a significant difference in pain levels, time to first
opioid, and overall opioid consumption between the two groups.
randomization to avoid bias. The control group will undergo split thickness autografting
using the standard protocol, involving injection of lidocaine with epinephrine at the donor
site. The experimental group will undergo injection of liposomal bupivacaine (Exparel) at the
time of harvest of the skin graft. Baseline pain levels will be obtained for all subjects
using a validated pain assessment scale. Postoperatively, time to first opioid pain
medication (excluding immediate postoperative recovery from anesthesia), total opioid
consumption on a daily basis, and donor site interval pain scores using a validated pain
assessment scale will be obtained. The experimental group will then be compared to the
control group to determine if there is a significant difference in pain levels, time to first
opioid, and overall opioid consumption between the two groups.
Inclusion Criteria:
- Spanish/English speaking
- <20%TBSA; <5% TBSA deep partial or full thickness burns
Exclusion Criteria:
- chronic pain syndrome
- > 20% TBSA burn injury; > 5% TBSA deep partial or full thickness burn
- pregnant
- allergy to lidocaine or other local anesthetics
- burns to anterior thighs
We found this trial at
1
site
Click here to add this to my saved trials
